93 / 103
U
se
of
anastrozole
in
the
chemoprevention
and
treatment
of
breast
cancer
: A
literature
review
R
ev
A
ssoc
M
ed
B
ras
2017; 63(4):371-378
377
matase. Embora alguns estudos tenham demonstrado
que as suas propriedades farmacodinâmicas e farmaco-
cinéticas podem ser afetadas pela variabilidade interindi-
vidual, esse fármaco tem sido recentemente utilizado em
todas as configurações de tratamento do câncer de mama.
Na doença metastática, é atualmente considerado o tra-
tamento de primeira linha emmulheres pós-menopáusi-
cas com tumores de mama e receptor de estrogênio posi-
tivo. O anastrozol temmostrado resultados promissores
no tratamento adjuvante do câncer de mama em estágio
inicial emmulheres na pós-menopausa. Ele também con-
seguiu resultados interessantes na quimioprevenção da
doença. Portanto, em virtude da importância do anastro-
zol tanto no tratamento endócrino quanto na quimio-
prevenção do câncer de mama hormoniossensível em
mulheres na pós-menopausa, propusemos a atual revisão
da literatura na base de dados SciELO e PubMed de arti-
gos publicados nos últimos 10 anos.
Palavras-chave:
inibidores da aromatase, quimiopreven-
ção, neoplasias da mama, farmacocinética.
R
eferences
1.
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer
J Clin. 2014; 64(1):52-62.
2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):E359-86.
3.
Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for
breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones.
Breast Cancer Res. 2004; 6(5):213-8.
4.
Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast
Cancer Collaborative Group. Endogenous sex hormones and breast cancer
in postmenopausal women: reanalysis of nine prospective studies. J Natl
Cancer Inst. 2002; 94(8):606-16.
5.
Lake DE, Hudis C. Aromatase inhibitors in breast cancer: an update. Cancer
Control. 2002; 9(6):490-8.
6.
Freedman OC, Verma S, Clemons MJ. Pre-menopausal breast cancer and
aromatase inhibitors: treating a new generation of women. Breast Cancer
Res Treat. 2006; 99(3):241-7.
7. Geisler J, Lønning PE. Aromatase inhibition: translation into a successful
therapeutic approach. Clin Cancer Res. 2005; 11(8):2809-21.
8.
Di Nardo G, Gilardi G. Human aromatase: perspectives in biochemistry
and biotechnology. Biotechnol Appl Biochem. 2013; 60(1):92-101.
9.
Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents
for treatment and prevention of breast cancer. Int J Clin Pract. 2007;
61(12):2051-63.
10. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ;
Panel members. Thresholds for therapies: highlights of the St Gallen
International Expert Consensus on the primary therapy of early breast
cancer 2009. Ann Oncol. 2009; 20(8):1319-29.
11.
Lombardi P. Exemestane, a new steroidal aromatase inhibitor of clinical
relevance. Biochim Biophys Acta. 2002; 1587(2-3):326-37.
12.
Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med.
2003; 348(24):2431-42.
13. Gobbi S, Rampa A, Belluti F, Bisi A. Nonsteroidal aromatase inhibitors for
the treatment of breast cancer: an update. Anticancer Agents Med Chem.
2014; 14(1):54-65.
14.
Pan K, Chlebowski RT. Adjuvant endocrine therapy of perimenopausal and
recently postmenopausal women with hormone receptor-positive breast
cancer. Clin Breast Cancer. 2014; 14(3):147-53.
15.
Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The
pharmacology of letrozole. J Steroid Biochem Mol Biol. 2003; 87(1):35-45.
16. Kelly CM, Buzdar AU. Anastrozole. Expert OpinDrug Saf. 2010; 9(6):995-1003.
17.
Buzdar AU. Pharmacology and pharmacokinetics of the newer generation
aromatase inhibitors. Clin Cancer Res. 2003; 9(1 Pt 2):468S-72S.
18.
Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons
from the laboratory. Nat Rev Cancer. 2003; 3(11):821-31.
19.
Sanford M, Plosker GL. Anastrozole: a review of its use in postmenopausal
women with early-stage breast cancer. Drugs. 2008; 68(9):1319-40.
20.
Bhatnaga AS. The discovery and mechanism of action of letrozole. Breast
Cancer Res Treat. 2007; 105(Suppl 1):7-17.
21.
Milani M, Jha G, Potter DA. Anastrozole use in early stage breast cancer of
postmenopausal women. Clin Med Ther. 2009; 31(1):141-56.
22.
Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, et al.
Variation in anastrozole metabolism and pharmacodynamics in women
with early breast cancer. Cancer Res. 2010; 70(8):3278-86.
23.
Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, et al.
Estrogens and their precursors in postmenopausal women with early breast
cancer receiving anastrozole. Steroids. 2015; 99(Pt A):32-8.
24.
Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser
A, et al. Potential role of UGT1A4 promoter SNPs in anastrozole
pharmacogenomics. Drug Metab Dispos. 2013; 41(4):870-7.
25.
Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, et al. In vitro
and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J
Clin Pharmacol. 2010; 70(6):854-69.
26. Wilkinson K. Anastrozole (Arimidex). Clin J Oncol Nurs. 2004; 8(1):87-8.
27. Abubakar MB, Wei K, Gan SH. The influence of genetic polymorphisms on
the efficacy and side effects of anastrozole in postmenopausal breast cancer
patients. Pharmacogenet Genomics. 2014; 24(12):575-81.
28.
Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F.
Clinical utility of exemestane in the treatment of breast cancer. Int J Womens
Health. 2015; 7:551-63.
29.
Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D,
et al. FACT: an open-label randomized phase III study of fulvestrant and
anastrozole in combination compared with anastrozole alone as first-line
therapy for patients with receptor-positive postmenopausal breast cancer.
J Clin Oncol. 2012; 30(16):1919-25.
30.
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR,
et al. Combination anastrozole and fulvestrant in metastatic breast cancer.
N Engl J Med. 2012; 367(5):435-44.
31.
Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al.;
SoFEA investigators. Fulvestrant plus anastrozole or placebo versus
exemestane alone after progression on non-steroidal aromatase inhibitors
in postmenopausal patients with hormone-receptor-positive locally advanced
or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3
randomised trial. Lancet Oncol. 2013; 14(10):989-98.
32.
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson
NE, et al. ; American Society of Clinical Oncology. American Society of
Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine
therapy for women with hormone receptor-positive breast cancer. J Clin
Oncol. 2010; 28(23):3784-96.
33. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors,
and breast cancer. J Steroid BiochemMol Biol. 2011; 125(1-2):13-22.
34. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al.; ATAC/
LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant
treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Lancet Oncol. 2010; 11(12):1135-41.
35. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch
A, Thürlimann B, Paridaens R, et al. Letrozole therapy alone or in sequence with
tamoxifen in women with breast cancer. N Engl J Med. 2009; 361(8):766-76.
36. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, et al.
Improved overall survival in postmenopausal women with early breast cancer
after anastrozole initiated aftertreatment with tamoxifen compared with
continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007; 25(19):2664-70.
37.
Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, et al.
Switching to anastrozole versus continued tamoxifen treatment of early
breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA)
trial. Ann Oncol. 2006; 17(Suppl 7):vii10-4.
38. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al.;
Intergroup Exemestane Study. A randomized trial of exemestane after two
to three years of tamoxifen therapy in postmenopausal women with primary
breast cancer. N Engl J Med. 2004; 350(11):1081-92.